Open access
Open access
Powered by Google Translator Translator

Oncology – Skin

Phase 2 RCT | Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma.

19 Sep, 2022 | 12:32h | UTC

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial – The Lancet (free registration required for full-text)

Commentary: Dual checkpoint inhibitor blockade shows promise as first-line and salvage therapy for Merkel cell carcinoma patients – H. Lee Moffitt Cancer Center & Research Institute

 


Phase 2 RCT | Sequencing of Ipilimumab plus Nivolumab and Encorafenib plus Binimetinib for untreated BRAF-mutated metastatic melanoma.

14 Sep, 2022 | 13:01h | UTC

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Sequential Treatment With Immunotherapy and Targeted Therapy Denotes OS Benefit in BRAF-Mutant Melanoma – OncLive

 

Commentary on Twitter

 


Phase 2 single-arm study | Neoadjuvant Cemiplimab for stage II to IV cutaneous squamous-cell carcinoma.

13 Sep, 2022 | 13:11h | UTC

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Neoadjuvant Cemiplimab Induces Promising Pathologic Complete Response in CSCC – Cancer Network

 

Commentary on Twitter

 


RCT | Five-year analysis of adjuvant Pembrolizumab or placebo in stage III melanoma.

13 Sep, 2022 | 13:03h | UTC

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma – NEJM Evidence

 


Phase 2 RCT | Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease.

11 Sep, 2022 | 22:25h | UTC

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial – The Lancet

 


3-year outcomes of a RCT | First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma.

2 Sep, 2022 | 13:04h | UTC

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 – Annals of Oncology

Original Study: Randomized trial: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma

Related: Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

 


Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management.

2 Sep, 2022 | 13:02h | UTC

Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management – International Journal of Dermatology

 


RCT | Optical coherence tomography vs. punch biopsy for diagnosis of basal cell carcinoma.

31 Aug, 2022 | 11:31h | UTC

Optical coherence tomography versus punch biopsy for diagnosis of basal cell carcinoma: a multicentre, randomised, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: 66% of diagnostic biopsies for common skin cancer can be avoided using Michelson Diagnostics’ VivoSight OCT laser scanner – PR Newswire

 


RCT | Talimogene Laherparepvec plus Pembrolizumab not better than placebo-Pembrolizumab in patients with advanced melanoma.

26 Aug, 2022 | 13:09h | UTC

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma – Journal of Clinical Oncology

 


RCT | Therapeutic value of sentinel lymph node biopsy in patients with melanoma.

4 Aug, 2022 | 14:05h | UTC

Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial – JAMA Surgery (free for a limited period)

Invited Commentary: Prognostic or Therapeutic—The Role of Sentinel Lymph Node Biopsy in Contemporary Practice – JAMA Surgery (free for a limited period)

 


Cohort Study | Clinical outcomes and risk stratification of early-stage melanoma micrometastases.

1 Aug, 2022 | 12:04h | UTC

Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease – Journal of Clinical Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Cohort Study | Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas.

1 Aug, 2022 | 12:03h | UTC

Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas – Journal of the American Academy of Dermatology International

Commentary: Margin Size Associated With Risk of Local Recurrence From Melanoma In Situ – AJMC

 


Single-arm phase 2 study | Lenvatinib plus Pembrolizumab for melanoma with confirmed progression on a PD-1 or PD-L1 inhibitor given as monotherapy or in combination.

1 Aug, 2022 | 11:48h | UTC

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: TKI Plus Immunotherapy Active in Melanoma After Anti-PD-1 Progression — More than a fifth of patients responded to lenvatinib-pembrolizumab combination – MedPage Today (free registration required)

 


NICE Guideline Update | Melanoma: assessment and management.

28 Jul, 2022 | 13:21h | UTC

Melanoma: assessment and management – National Institute for Health and Care Excellence

 


RCT | Efficacy and safety of topical hypericin photodynamic therapy for early-stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides).

28 Jul, 2022 | 13:09h | UTC

Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial – JAMA Dermatology (free for a limited period)

 

Commentary on Twitter

 


RCT | Follow-up schedule for patients with sentinel node negative cutaneous melanoma.

25 Jul, 2022 | 12:43h | UTC

Follow-up Schedule for Patients with Sentinel Node Negative Cutaneous Melanoma: an International Phase III Randomised Clinical Trial – Annals of Surgery (link to abstract – $ for full-text)

 


5-year outcomes of a RCT | Encorafenib plus Binimetinib vs. Vemurafenib or Encorafenib in patients with BRAF V600–mutant melanoma.

25 Jul, 2022 | 12:41h | UTC

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma – Journal of Clinical Oncology

Editorial: What, if Any, Role Is There for BRAF-Targeted Therapy in BRAF-Mutant Melanoma? – Journal of Clinical Oncology

 


M-A | Does it really pay-off? Comparison of lymphadenectomy versus observational approach in skin melanoma with positive sentinel node biopsy.

12 Jul, 2022 | 12:37h | UTC

Does It Really Pay-Off? Comparison of Lymphadenectomy versus Observational Approach in Skin Melanoma with Positive Sentinel Node Biopsy: Systematic Review and Meta-Analysis – Journal of Clinical Medicine

 


M-A | Associations of thiazide use with skin cancers.

8 Jul, 2022 | 11:55h | UTC

Associations of thiazide use with skin cancers: a systematic review and meta-analysis – BMC Medicine

Related:

Association between antihypertensive medications and risk of skin cancer in people older than 65 years: a population-based study – Canadian Medical Association Journal

Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma – JAMA Internal Medicine

Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark – Journal of the American Academy of Dermatology

 


M-A | Adjuvant treatments of adult melanoma.

7 Jul, 2022 | 12:12h | UTC

Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis – Frontiers in Oncology

 


Consensus Guideline: Diagnosis and treatment of Merkel cell carcinoma.

28 Jun, 2022 | 11:07h | UTC

Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022 – European Journal of Cancer

 


Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts.

23 Jun, 2022 | 09:57h | UTC

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment – Journal of Clinical Oncology

 


ASCO Guideline Update: Systemic therapy for melanoma.

14 Jun, 2022 | 11:00h | UTC

Systemic Therapy for Melanoma: ASCO Guideline Rapid Recommendation Update – Journal of Clinical Oncology

 


Systematic Review: Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings.

10 Jun, 2022 | 10:28h | UTC

Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings: a systematic review – The Lancet Digital Health

 

Commentary on Twitter

 


RCT: Effect of reflectance confocal microscopy for suspect lesions on diagnostic accuracy in melanoma.

2 Jun, 2022 | 10:41h | UTC

Effect of Reflectance Confocal Microscopy for Suspect Lesions on Diagnostic Accuracy in Melanoma: A Randomized Clinical Trial – JAMA Dermatology

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.